PCN354 Treatment Patterns Among Front-Line Glioblastoma Patients In Five European Countries  by Jiang, S et al.
A492  VA L U E  I N  H E A LT H  1 8  ( 2 0 1 5 )  A 3 3 5 – A 7 6 6  
fees under the routine continuous chemotherapies were RMB11,333 (USD1,828) per 
patient, with 34.8% (RMB3,939) born by the patient out-of-pocket. Under PAP, for the 
same patient group, the patients monthly self-paid RMB4,519 (USD729) of the aver-
age fees for Icotinib and another RMB1,064 (USD172, 16.9% of total fees) for other 
drugs and routine treatment. ConClusions: The PAP, which provides the targeted 
patients the access to innovative medicines with better efficacy and safety, greatly 
decreased the fees on routine treatment, but also brought additional self-paid cost 
on PAP-covered medicines. Further researches are needed to help decision makers 
to make the tradeoff among better accessibility, increasing cost and improved out-
comes from the clinical utilization of PAP-covered innovative medicines.
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objeCtives: To describe demographic and clinical characteristics and real-world 
treatment patterns for post-menopausal patients with ER+/HER2- metastatic breast 
cancer (MBC) in the United Kingdom (UK). Methods: We conducted a retrospective 
review of medical records from institutions across the UK. Records were eligible for 
abstraction if patients were post-menopausal, had ER+/HER2- MBC (stage IV), and 
had discontinued second-line treatment in the metastatic setting between 1/1/2008 
and 3/1/2014. Patients who participated in clinical trials were excluded. This study 
was considered a “Service Evaluation” by National Research Ethical Service guid-
ance, thus ethics review was not required. Patient demographic, clinical character-
istics and treatment patterns including time to progression (TTP) and treatment 
discontinuation were assessed. Results: Forty-one medical/ clinical oncologists 
provided information for 209 patients. Patients were aged 62 years on average and 
predominantly Caucasian (87%), with 68% diagnosed in metastatic stage and 32% 
progressed from earlier stages. Bone was the most common site of metastasis (66%) 
followed by lung/pleura (50%), liver (41%), and lymph nodes (35%). In the first-line 
MBC setting, 49% of patients received endocrine therapy alone, 6% received it in 
combination with chemotherapy, 15% received it following chemotherapy induction, 
and 30% received chemotherapy alone. Chemotherapy usage increased in subse-
quent therapy lines (33% in second-line [n= 209]; 53% in third-line [n= 116]). Disease 
progression was the primary reason for discontinuing treatment in both first- and 
second-line (60% and 68% respectively). During first-line treatment, 86% progressed, 
with median TTP of 9.5 months. In second-line, 79% progressed, with median TTP of 
7 months. ConClusions: Endocrine therapy and chemotherapy were commonly 
prescribed for ER+/HER2- MBC patients. Disease progression remains the most com-
mon reason for stopping/ changing therapies, with median TTP < 1 year. These 
findings suggest that there is a continuing unmet need for new treatments that can 
extend TTP and address the potential limitations of current therapies.
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objeCtives: To describe the real-world treatment patterns of current melanoma 
therapies among patients with metastatic melanoma in the US. Methods: A ret-
rospective cohort analysis was conducted using the IMS PharMetrics Plus claims 
database. Patients were included in the analysis if: ≥ 1 prescription for ipilimumab, 
vemurafenib, temozolomide, or dacarbazine between 1/1/2011-8/31/2013 (the date 
of the first use as the index date and the drug as the index drug); diagnosis of 
melanoma (ICD-9-CM 172.x, V10.82) and metastasis (ICD-9-CM 196.x-198.x) before 
the index date (pre-index); no index drug use pre-index date; continuous health 
plan enrollment for ≥ 6 months before and ≥ 3 months after the index date; age ≥ 18 
years. Treatment duration was assessed from the index date until a gap in days 
supplied for > 90 days, or the end of follow-up, whichever came first. Proportion 
of days covered (PDC) was defined as days exposed to the index therapy divided 
by continuously-enrolled days between the index date and the last prescription 
date of the index drug. Results: 1,043 patients with metastatic melanoma were 
included, with a median age of 57 years (43% ≤ 55 years), and 62% male. 405 patients 
received the index drug of ipilimumab, 361 vemurafenib, 203 temozolomide, and 
74 dacarbazine. Mean (median) treatment duration with vemurafenib, temozolo-
mide and dacarbazine was 174 (148), 100 (59) and 64 (52) days, respectively. Mean 
PDC with vemurafenib, temozolomide and dacarbazine was 81%, 67% and 51%, 
respectively. For patients receiving ipilimumab, 58% (234/405) had the full 4 doses, 
20% (79/405) had 3 doses only, 14% (57/405) had 2 doses only, and 9% (35/405) had 1 
dose only for the first treatment course; 4% (10/234) received re-treatment, and no 
patients had a second re-treatment. ConClusions: This study provides evidence 
of current treatment patterns of melanoma therapies, including newer agents, in 
the real-world clinical practice.
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objeCtives: To characterize real-world treatment patterns among front-
line patients with glioblastoma in Germany, France, Italy, UK, and Spain (EU-
5). Methods: This study used the oncologist-surveyed data from the IMS LifeLink™ 
Oncology Analyzer database. Front-line patients aged ≥ 20 years and diagnosed 
with glioblastoma during 2012 to 2014 in the EU-5 countries were included. Patient 
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objeCtives: To evaluate the economic results of this PbR compared to a traditional 
purchasing model and determine the perception of the stakeholders involved in 
the agreement. In healthcare systems, incentive-based schemes generally called 
payment-by-results schemes (PbR), which dynamically link the price of innovation 
to the usage conditions are alternatives to traditional fixed payment schemes. 
In 2011, the first PbR in Catalonia was signed between the Catalan Institute of 
Oncology, the Catalan Health Service and AstraZeneca (AZ) for the introduction 
of gefitinib in the treatment of EGFR-mutation positive advanced non-small-cell 
lung cancer. Methods: Economic analysis of the differential costs between two 
scenarios, one including the total cost of treatment and the PbR scenario where 
AZ reimbursed the treatment according to previously agreed terms. 41 patients 
were included from June 2011 to October 2013 and assessed at two evaluation 
points. At week 8, responses, stabilization and progression were evaluated and 
at week 16 stabilization was confirmed. AZ was to reimburse the total cost of 
treatment of those patients that failed the treatment. A qualitative research of 
the organizational elements was done by interviewing the parties involved in the 
contract Results: The difference in cost of gefinitib using the PbR compared to 
the traditional purchasing scenario was 6.17% less at 8 weeks, 11.18% at 16 weeks 
and 4.15% less for the overall treatment. The PbR resulted in total savings of around 
€ 36,000, which corresponds to approximately € 1,000 per patient. From an opera-
tional and organizational perspective, the availability of adequate information 
systems to measure outcomes and monitor accountability and the involvement of 
healthcare professionals were acknowledged as crucial. ConClusions: The par-
ties have identified tangible and intangible benefits with respect to the interests 
of the parties involved. This has led to the incorporation of innovation for patients 
under acceptable conditions.
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objeCtives: Risk-sharing scheme (RSS) has been implemented since Nov 2013 
as part of policies to increase patients’ accessibility in Korea. This study aimed 
to compare the impact of reimbursement rate before and after the implementa-
tion of RSS especially in anticancer drugs and to review the characteristics of the 
anticancer drugs on risk-sharing agreement (RSA). Methods: Reviewed appraisal 
results for anticancer drugs in HIRA Drug Reimbursement Assessment Committee 
from 2007 to Jun 2015. The rate of reimbursement recommendation before and after 
RSS implementation and the proportion of RSA after RSS implementation were 
assessed. Drugs recommended after RSS implementation were classified into com-
parative clinical effectiveness-superior, non-inferior, similar- and cost effectiveness-
assessed by economic analysis or weighted average price. From each category, the 
proportion of RSA drug and type of scheme were counted. Results: During 8.5 
years, total 86 appraisals of anticancer drugs, the reimbursement recommendation 
rate was 58.1%(50/86). The reimbursement recommendation rate was 55.4%(31/56) 
before RSS implementation and 63.3%(19/30) after RSS implementation. After RSS 
implementation, 19 appraisals of anticancer drugs were reimbursement, 10 of them 
were reimbursement on the condition of RSA (53%), and types of RSS were refund 
(100%). As for comparative clinical effectiveness of among 19 appraisals after RSS 
implementation, 16 were superior, 3 were silimilar to comparator. Among ‘superior’ 
group, 12 were assessed by economic analysis (CUA), 6 of them were on RSA (50%). 
The number of appraisals not assessed by economic analysis in superior group was 
4, and they were on RSA. In ‘similar’ group, all were assessed by weighted average 
price and none of them were on RSA. ConClusions: The implementation of RSS 
seemed to contribute to increase patients’ accessibility to new anticancer drugs. RSS 
can be a compensating way to decision-making for reimbursement of anticancer 
drugs which are clinically beneficial but having uncertainty in cost-effectiveness.
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objeCtives: A patient access program (PAP) was adopted by local health insur-
ance scheme in Qingdao since 2012 to provide the coverage of innovative products 
for catastrophic diseases including non-small cell lung cancer. This study aims to 
measure the impact of PAP on economic burden of the patients with non-small cell 
lung cancer. Methods: The patients with non-small cell lung cancer during 2008 
and 2013 were identified from health insurance information system. All claims data, 
including total treatment fees, the composition and the out-of-pocket fees born by 
the patients, were collected and a comparative analysis before and after the PAP 
implementation was conducted. Results: The PAP was achieved through price 
negotiation between local health insurance agent and manufacturers and reim-
bursed 70% of the cost of PAP-covered innovative medicines including Icotinib for 
non-small cell lung cancer. Totally 299 new patients with non-small cell lung cancer 
registered in PAP and another 78 patients were identified to switch from routine 
chemotherapies into Icotinib regimen. Before PAP, the average monthly treatment 
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primary treatment goals were reductions of the risk of bone complications and 
associated bone pain.
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objeCtives: Clinical guidelines now are commonly used in many settings, though 
the impact of these guidelines on real world practice remains less clear. The 
USPSTF recently dropped recommendations for breast cancer screening among 
women aged 75+ years. Prior studies using survey data suggest that the guideline 
revision had no effect on screening behavior. Using registry and claims data, we 
assessed changes in screening patterns, and stage at diagnosis, among female 
Medicare beneficiaries aged 75+years compared with 65-74 years. Methods: 
We examined 2003-11 biennial mammography screening rates using national 
Medicare fee-for-service claims (20% random sample), and linked SEER registry-
Medicare claims databases. Using linear regression models with a patient-level 
fixed effect, we estimated the change in proportion of subjects receiving screening 
over time (as well as the rate of incident cases of earlier vs. later stage cancer), 
among subjects aged 75+yo compared with younger subjects, i.e., a difference-in-
difference design. Results: We find a decrease in screening rate among women 
aged 75+ years after the revision (2011 vs. 2003-2008, and the difference in changes 
compared with younger women was 13.2% (95%CI:13.1-13.3%). Similarly, we find 
a relative decrease in the population rate of incident cases of earlier-stage cancer 
(0.12%, 95%CI: 0.07-0.17), increases in later-stage cancer. ConClusions: With the 
guideline revision, there were relative decreases in screening rates among women 
aged 75+ years, compared with younger women. There also was a breast cancer 
stage shift, with more later-stage cancers and fewer earlier-stage cancers detected. 
Future evaluations on survival are needed. Moreover, as health insurance plans 
increasing link benefit designs with guidelines, the likelihood that guidelines will 
impact practice patterns could grow.
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objeCtives: To compare the treatment patterns and resulting quality adjusted 
life year (QALY) in patients of Head & Neck cancers under private payment scheme 
(PPS) and government scheme (GS). Methods: In a prospective study treatment 
orders of patients on chemotherapy for head & neck cancers were reviewed and 
patients were interviewed for six treatment cycles to assess treatment patterns in 
an oncology hospital having dedicated wards for patients under GS. Direct medi-
cal cost, indirect medical cost and non-medical costs associated with treatment 
were calculated for patients under PPS and GS and were compared. EQ-5D-5L 
instrument was administered to assess patient utility with treatment during 
each cycle. Results: A total of 104 patients (n= 49 under PPS, n= 55 under GS) 
were enrolled in the study after obtaining their informed consent. Majority of the 
patients under PPS were on Paclitaxel based regimen (63%) followed by primary 
protocol ((Docetaxel+ Cyclophosphamide+ Fluorouracil, (8%)). Most of the patients 
under GS were treated with Cisplatin with radiation therapy (82%) and none of the 
eligible patients under GS had privilege of treatment with primary protocol due 
to limited budget. Treatment compliance to NCCN guidelines for patients under 
PPS and GS was 89% and 58% respectively. Common adverse events like vomiting, 
constipation, neutropenia, fatigue and myalgia were higher in patients under GS 
than PPS. Average cost of treatment for PPS and GS per cycle was US $125 and US $30 
respectively. QALY gained by patients under PPS and GS after six cycles was 0.024 
and 0.014 respectively and the difference was found to be statistically significant 
(p< 0.05). ConClusions: Treatment patterns in patients under PPS were well com-
pliant to NCCN guidelines. Limited budget of government scheme in a developing 
country does not allow clinicians to prescribe required anti-cancer medicines and 
supportive care. Patients under GS can be benefited with more utility with additional 
increment in the budget.
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objeCtives: This signal detection pharmacovigilance activity aims to determine 
if treatment with desloratadine is associated with more than expected report-
ing of torsade de pointes and electrocardiogram QT prolongation (TQP) events 
in real-world settings. Methods: Adverse event reports submitted to the FDA 
Adverse Event Reporting System were used (cumulative to June 2014), and Multi-
item Gamma Poisson Shrinker disproportionality analysis algorithm was applied 
to calculate Empirical Bayes Geometric Mean (EBGM) and corresponding 95%CI as 
association metrics. Desloratadine was defined by generic name, and ventricular 
tachycardia events were defined as structured MedDRA queries of Preferred Terms 
denoting to TQP. Reporting profile was compared to loratadine, the parent drug of 
desloratadine. Arrhythmogenic antihistamines, astemizole and terfenadine, were 
used as positive controls. Results: Seventeen reports of TQP were submitted 
for desloratadine corresponding to 59% male users (mean age 44 years), and 17% 
and 35% of TQP events were life-threatening and lead to patient hospitalization, 
demographics, comorbidities, therapy type, treatment initiator, and concomitant 
medications were descriptively examined across the EU-5 and by individual coun-
try. Results: A total of 64,932 patients from Germany (24,577), France (12,574), 
Italy (11,676), UK (8,427), and Spain (7,698) were included. The majority were male 
(64%, except Germany was 50%), > 56 years (70%), and had chemo-radiation (91%). 
Comorbidities were similar across countries, except COPD (5%, whereas Spain was 
19%) and Cardiac Dysfunction (4%, whereas Germany was 21%). Except in the UK, 
temozolomide was used, on average, for 82% of front-line patients with treatment 
being initiated by a radiologist (58%) or medical oncologist (23%). In the UK, temo-
zolomide was used for 65% of front-line patients and was initiated by a radiologist 
90% of the time. Surgical procedures including Excision of Lesion, Craniotomy, and 
Lobectomy were performed, on average, in 67% of patients, except in France (44%). 
However, French patients were more likely to have a Burr Hole Biopsy (43%) versus 
the other 4 countries (average of 20%). Frequently used concomitant medications 
were corticosteroids (3-fold variation across EU-5), anti-emetics (5-fold variation), 
and gastrointestinal medications (on average 20%). ConClusions: The common 
front-line treatment for glioblastoma was found to be surgery followed by temozolo-
mide chemotherapy, consistent with guidelines. However, there was some variation 
across countries with regards to the type of surgery, comorbidities, chemotherapy 
initiator, and concomitant medications. Further study is needed to comprehensively 
characterize glioblastoma treatment patterns in the EU-5.
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objeCtives: To examine bone pain and BTA treatment patterns in patients with 
BMs from BC in real-world setting in Europe. Methods: The study was conducted 
using the Adelphi Breast Cancer Disease-Specific Programme (DSP) 2015 database, a 
multi-country cross-sectional survey of 385 oncologists from 6 European countries 
(UK, Germany, France, Italy, Spain, and Belgium). Each physician completed a patient 
record form (PRF) for 10 patients being treated for advanced BC that captured the 
following information: presence of BMs, current pain state, current analgesic use, 
BTA treatment, and reasons behind BTA treatment decisions. Results: A total 
of 1376 patients with BM from BC were identified. At the time of survey (an aver-
age of 11 months after diagnosis of BMs), 47% of the patients experienced mild 
pain; and 20% had moderate/severe pain. The majority of the patients (96%) with 
pain took analgesic drugs to manage pain, which included 28% (n= 260) patients 
treated with strong opioids (e.g. morphine, oxycodone etc.). Of them, 59% (154/260) 
still experienced moderate/severe bone pain. Among the patients with BMs, 88% 
(n= 1210) were treated with a BTA. Of them, 81% (n= 979) received treatment within 
3 months of BMs diagnosis. Reasons for BTA treatment initiation within 3 months 
of BMs were “bone pain” (34%), “high risk of bone complications” (31%), “number of 
BMs” (13%), “location of BMs” (8%) and “prior history of bone complications” (7%). 
Reasons for not treating patients with BTAs were “recent diagnosis” (40%), “low bone 
complication risk” (17%), “focus on treating primary tumor” (10%), and “short life 
expectancy” (10%). ConClusions: Bone pain is the main symptom encountered 
by patients with BMs from BC. Most of these patients treated with strong opioids 
still experienced moderate/severe bone pain. The majority of patients with BMs 
received BTAs; primary treatment goals were reductions of bone pain and risk of 
bone complications.
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objeCtives: To examine bone pain and BTA utilization in patients with BMs from 
PC in real-world setting in Europe. Methods: This study was conducted using 
the Adelphi Prostate Cancer Disease Specific Programme (DSP) 2015 database, a 
multi-country cross-sectional survey of 241 oncologists and 103 urologists in 6 
European countries (UK, Germany, France, Italy, Spain, and Belgium). Patients’ 
current pain state, current analgesic use, BTA treatment, and reasons for BTA 
treatment data were extracted from the patient record forms (PRFs) completed 
by the physicians. Results: A total of 3608 PRFs were collected including 1931 on 
PC patients with BMs. At the time of survey (an average of 15.2 months from BMs 
diagnosis), 41% patients experienced mild pain; and 29% had moderate/severe 
bone pain. The majority of the patients (96%) with pain took analgesics to manage 
pain, including 29% (n= 387) patients who were treated with strong opioids (e.g. 
morphine, oxycodone etc.). Of these patients, 73% (284/387) still had moderate/
severe pain. Among the patients with BMs, 74% (n= 1437) were treated with a BTA, 
and BTA treatment occurred within 3 months of BMs diagnosis in 72% (n= 1036) 
of them. Reasons for BTA treatment initiation within 3 months of BMs were “bone 
pain” (40%), “high risk of bone complications” (29%), “number of BMs” (11%), “loca-
tion of BMs” (8%) and “prior history of bone complications” (5%). Reasons for not 
treating patients with BTA were “recent diagnosis” (36%), “low bone complication 
risk” (22%), and “focus on treating primary tumor” (8%). ConClusions: Bone pain 
is the major symptom encountered by patients with BMs from PC. The majority 
of these patients treated with strong opioids still experienced moderate/severe 
bone pain. Approximately three quarters of patients with BMs received BTAs; 
